Cited by 418Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Selective cytotoxicity of intracellular amyloid β peptide1–42 through p53 and Bax in cultured primary human neurons

Open access
Zhang, Yan, McLaughlin, Richard, Goodyer, Cynthia, LeBlanc, Andréa·2002·The Journal of Cell Biology

Abstract

Extracellular amyloid β peptides (Aβs) have long been thought to be a primary cause of Alzheimer's disease (AD). Now, detection of intracellular neuronal Aβ1–42 accumulation before extracellular Aβ deposits questions the relevance of intracellular peptides in AD. In the present study, we directly address whether intracellular Aβ is toxic to human neurons. Microinjections of Aβ1–42 peptide or a cDNA-expressing cytosolic Aβ1–42 rapidly induces cell death of primary human neurons. In contrast, Aβ1–40, Aβ40–1, or Aβ42–1 peptides, and cDNAs expressing cytosolic Aβ1–40 or secreted Aβ1–42 and Aβ1–40, are not toxic. As little as a 1-pM concentration or 1500 molecules/cell of Aβ1–42 peptides is neurotoxic. The nonfibrillized and fibrillized Aβ1–42 peptides are equally toxic. In contrast, Aβ1–42 peptides are not toxic to human primary astrocytes, neuronal, and nonneuronal cell lines. Inhibition of de novo protein synthesis protects against Aβ1–42 toxicity, indicating that programmed cell death is involved. Bcl-2, Bax-neutralizing antibodies, cDNA expression of a p53R273H dominant negative mutant, and caspase inhibitors prevent Aβ1–42-mediated human neuronal cell death. Taken together, our data directly demonstrate that intracellular Aβ1–42 is selectively cytotoxic to human neurons through the p53–Bax cell death pathway.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1083/jcb.200110119

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intraneuronal Aβ42 accumulation in 5XFAD mice is either transient or obscured by plaque staining as mice age.

    “suggesting that either intraneuronal Aβ42 accumulation is transient [27], or intracellular Aβ42 signal is obscured as plaque staining intensifies with age.”

    From Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation (2013) · cites this paper as [27]

    The Introduction and Discussion say intracellular Aβ42 can appear before plaques, including in some transgenic mice, but neither says its accumulation is transient. Searches for transient accumulation and age-related plaque staining found no supporting passage. The citation is attached to the transient-accumulation possibility, not the separate suggestion that plaque staining obscures the signal; the paper does not discuss 5XFAD mice. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Intraneuronal Aβ1-42 is particularly neurotoxic in vitro and in vivo.

    “Intriguing in vitro and in vivo studies showed that intraneuronal Aβ1-42 was particularly neurotoxic [213]”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Terry, R.D. 1999. The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. Alzheimer Disease. R.D. Terry, editor. Lippincott, Williams and Wilkins, Philadelphia. 187–206.

Cited by

Sorted by citations

Authors
Zhang, Y., McLaughlin, R., Goodyer, C., & LeBlanc, A.
Affiliations
  • Jewish General Hospital (CA)
  • 3Neurochem, Inc., Ville Saint-Laurent, Québec H4S 2A1, Canada
  • McGill University (CA)
  • 1Department of Neurology and Neurosurgery, McGill University, Montréal, Québec H3A 2T5, Canada
Venue
The Journal of Cell Biology
Published
2002-01-28
Volume
156
Issue
3
Pages
519-529
ISSN
  • 0021-9525 (ISSN-L)
  • 1540-8140
OpenAlex
W2007922488
Cited by
418
References
61
Citations by year
2026: 2 · 2025: 11 · 2024: 13 · 2023: 5 · 2022: 8 · 2021: 8 · 2020: 11 · 2019: 8 · 2018: 11 · 2017: 9 · 2016: 8 · 2015: 15 · 2014: 21 · 2013: 23 · 2012: 18
FWCI
19.98
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Cell Biology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
intracellular amyloid-beta, amyloid-beta 42, neurotoxicity, neuronal cell death, p53, Bax, Alzheimer's disease, programmed cell death, caspases, Bcl-2, protein synthesis inhibition
MeSH terms
Alzheimer Disease, Astrocytes, Brain, Cells, Cultured, Enzyme Inhibitors, Fetus, Humans, Intracellular Fluid, Microscopy, Electron, Neurons, Peptide Fragments, Polymers, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Amyloid beta-Peptides, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Caspases, bcl-2-Associated X Protein, Plaque, Amyloid, Caspase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review